| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Tumor Cell Biology [J. D., M-L. K., L. S., C. J. S., M. F. R.], Biochemistry [C. M. E.], and Howard Hughes Medical Institute [L. S., C. J. S.], St. Jude Children’s Research Hospital, Memphis, Tennessee 38105
Mdm2 is a p53-inducible phosphoprotein that negatively regulates p53 by binding to it and promoting its ubiquitin-mediated degradation. Alternatively spliced variants of Mdm2 have been isolated from human and mouse tumors, but their roles in tumorigenesis, if any, remain elusive. We cloned six alternatively spliced variants of Mdm2 from Eµ-Myc-induced mouse lymphomas, all of which lacked the NH2-terminal p53-binding domain but conserved the remainder of the Mdm2 protein. Enforced expression of full-length Mdm2 in primary mouse embryo fibroblasts or bone marrow-derived, interleukin 7-dependent pre-B cells accelerated their proliferation, whereas unexpectedly, overexpression of truncated Mdm2 isoforms inhibited their growth. Truncated variants were active as inhibitors whether they localized predominantly to the nucleus or cytoplasm. Despite the absence of the p53-binding domain, growth inhibition remained strictly p53 dependent (but not p19Arf dependent) and could be overcome by full-length Mdm2. The intact RING finger domain at the Mdm2 COOH terminus (amino acids 399–489) was necessary and sufficient for growth inhibition by truncated Mdm2 proteins and could physically interact with either the RING finger domain or central acidic region of full-length Mdm2. However, such interactions do not inhibit Mdm2 E3 ubiquitin ligase activity in vitro using p53 as a substrate. Expression of growth-inhibitory Mdm2 isoforms in tumors remains an enigma.
This article has been cited by other articles:
|
|
 |
|
  L. E. Giono and J. J. Manfredi Mdm2 Is Required for Inhibition of Cdk2 Activity by p21, Thereby Contributing to p53-Dependent Cell Cycle Arrest Mol. Cell. Biol., June 1, 2007; 27(11): 4166 - 4178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schuster, L. Fan, and L. C. Harris MDM2 Splice Variants Predominantly Localize to the Nucleoplasm Mediated by a COOH-Terminal Nuclear Localization Signal Mol. Cancer Res., April 1, 2007; 5(4): 403 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Chandler, R. K. Singh, L. C. Caldwell, J. L. Bitler, and G. Lozano Genotoxic Stress Induces Coordinately Regulated Alternative Splicing of the p53 Modulators MDM2 and MDM4 Cancer Res., October 1, 2006; 66(19): 9502 - 9508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tago, S. Chiocca, and C. J. Sherr Sumoylation induced by the Arf tumor suppressor: A p53-independent function PNAS, May 24, 2005; 102(21): 7689 - 7694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Alt, A. Bouska, M. R. Fernandez, R. L. Cerny, H. Xiao, and C. M. Eischen Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair J. Biol. Chem., May 13, 2005; 280(19): 18771 - 18781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhou, R. Frum, S. Deb, and S. P. Deb The Growth Arrest Function of the Human Oncoprotein Mouse Double Minute-2 Is Disabled by Downstream Mutation in Cancer Cells Cancer Res., March 1, 2005; 65(5): 1839 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brady, N. Vlatkovic, and M. T. Boyd Regulation of p53 and MDM2 Activity by MTBP Mol. Cell. Biol., January 15, 2005; 25(2): 545 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Wang, R.-K. Lin, Y.-H. Tan, J.-T. Chen, C.-Y. Chen, and Y.-C. Wang Wild-Type p53 Overexpression and Its Correlation With MDM2 and p14ARF Alterations: An Alternative Pathway to Non-Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2005; 23(1): 154 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Steinman, E. Burstein, C. Lengner, J. Gosselin, G. Pihan, C. S. Duckett, and S. N. Jones An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis J. Biol. Chem., February 6, 2004; 279(6): 4877 - 4886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bartel, L. C. Harris, P. Wurl, and H. Taubert MDM2 and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides Mol. Cancer Res., January 1, 2004; 2(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Iwakuma and G. Lozano MDM2, An Introduction Mol. Cancer Res., December 1, 2003; 1(14): 993 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Deb Cell Cycle Regulatory Functions of the Human Oncoprotein MDM2 Mol. Cancer Res., December 1, 2003; 1(14): 1009 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Fridman, E. Hernando, M. T. Hemann, E. de Stanchina, C. Cordon-Cardo, and S. W. Lowe Tumor Promotion by Mdm2 Splice Variants Unable to Bind p53 Cancer Res., September 15, 2003; 63(18): 5703 - 5706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Meulmeester, R. Frenk, R. Stad, P. de Graaf, J.-C. Marine, K. H. Vousden, and A. G. Jochemsen Critical Role for a Central Part of Mdm2 in the Ubiquitylation of p53 Mol. Cell. Biol., July 15, 2003; 23(14): 4929 - 4938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-L. Kuo, E. J. Duncavage, R. Mathew, W. den Besten, D. Pei, D. Naeve, T. Yamamoto, C. Cheng, C. J. Sherr, and M. F. Roussel Arf Induces p53-dependent and -independent Antiproliferative Genes Cancer Res., March 1, 2003; 63(5): 1046 - 1053. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
